Interferon beta (IFN-beta)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)0.97 [0.52, 1.81]0%6 studies5,034456serious ROB-
Major congenital malformations0.90 [0.44, 1.87]0%5 studies5,022387not evaluable ROB-
Congenital cataract--0 study-
1 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)1.11 [0.61, 2.03]70%6 studies383686not evaluable ROB-
Low birth weight (< 2500g)5.76 [1.52, 21.84]-1 study1117not evaluable ROB11.00 [2.41; .]
1 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
7 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Jaundice0.98 [0.29, 3.26]0%2 studies14108not evaluable ROB-
Neonatal death (< 28 days of life)1.37 [0.14, 13.46]0%2 studies2268not evaluable ROB-
Neonatal disorders (as a whole)5.53 [1.72, 17.79]-1 study1717not evaluable ROB10.54 [2.83; .]
1 non statistically significant endpoints reported in only one study

Long term consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
2 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Intrauterine deaths (as a whole or unspecified)1.16 [0.61, 2.22]23%4 studies95401not evaluable ROB-
Early intrauterine death (< 22 weeks)1.40 [0.82, 2.38]0%3 studies77361not evaluable ROB-
Elective/induced termination of pregnancy2.57 [0.28, 23.52]66%3 studies51641not evaluable ROB-
Late intrauterine deaths (> 22 weeks)1.96 [0.36, 10.54]0%3 studies5361not evaluable ROB-
1 non statistically significant endpoints reported in only one study

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
8 non statistically significant endpoints reported in only one study